Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D D Schoepp

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|December 8, 1995
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonistP L Ornstein, M B Arnold, N K Allen, et al.
Journal of Medicinal Chemistry|August 21, 1992
NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomerP L Ornstein, D D Schoepp, M B Arnold, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonistsP L Ornstein, M B Arnold, W H Lunn, et al.
European Journal of Pharmacology|October 15, 1991
D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonistD D Schoepp, C L Smith, D Lodge, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acidM J Valli, D D Schoepp, R A Wright, et al.
Molecular Pharmacology|April 1, 1996
Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acidR Bleakman, D D Schoepp, B Ballyk, et al.
Brain Research. Developmental Brain Research|October 15, 1993
Neonatal exposure to D,L-2-amino-3-phosphonopropionate (D,L-AP3) produces lesions in the eye and optic nerve of adult ratsA S Fix, D D Schoepp, J W Olney, et al.
Molecular Pharmacology|July 1, 1992
Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunitR K Kamboj, D D Schoepp, S Nutt, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490)D D Schoepp, C R Salhoff, K S Fuson, et al.
Journal of Medicinal Chemistry|November 27, 1992
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacyW H Lunn, D D Schoepp, D O Calligaro, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|December 8, 1995
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonistP L Ornstein, M B Arnold, N K Allen, et al.
Journal of Medicinal Chemistry|August 21, 1992
NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomerP L Ornstein, D D Schoepp, M B Arnold, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonistsP L Ornstein, M B Arnold, W H Lunn, et al.
European Journal of Pharmacology|October 15, 1991
D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonistD D Schoepp, C L Smith, D Lodge, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acidM J Valli, D D Schoepp, R A Wright, et al.
Molecular Pharmacology|April 1, 1996
Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acidR Bleakman, D D Schoepp, B Ballyk, et al.
Brain Research. Developmental Brain Research|October 15, 1993
Neonatal exposure to D,L-2-amino-3-phosphonopropionate (D,L-AP3) produces lesions in the eye and optic nerve of adult ratsA S Fix, D D Schoepp, J W Olney, et al.
Molecular Pharmacology|July 1, 1992
Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunitR K Kamboj, D D Schoepp, S Nutt, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490)D D Schoepp, C R Salhoff, K S Fuson, et al.
Journal of Medicinal Chemistry|November 27, 1992
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacyW H Lunn, D D Schoepp, D O Calligaro, et al.
Pageof 13